These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 9865331

  • 1. Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides.
    Schorlemmer HU, Bartlett RR.
    Transplant Proc; 1998 Dec; 30(8):4153-5. PubMed ID: 9865331
    [No Abstract] [Full Text] [Related]

  • 2. Malononitrilamides prevent the development of murine systemic lupus erythematosus-like diseases in BDF1 hybrid mice and MRL/lpr autoimmune mice.
    Schorlemmer HU, Brendel S, Bartlett RR.
    Transplant Proc; 1996 Dec; 28(6):3040-2. PubMed ID: 8962180
    [No Abstract] [Full Text] [Related]

  • 3. Malononitrilamides inhibit the development of various murine graft-vs-host diseases.
    Schorlemmer HU, Kurrle R, Bartlett RR.
    Transplant Proc; 1996 Dec; 28(6):3043-7. PubMed ID: 8962181
    [No Abstract] [Full Text] [Related]

  • 4. Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis.
    Schorlemmer HU, Bartlett RR, Schleyerbach R.
    Transplant Proc; 1998 Dec; 30(8):4137-9. PubMed ID: 9865326
    [No Abstract] [Full Text] [Related]

  • 5. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus.
    Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R.
    Transplant Proc; 1998 Dec; 30(8):4099-103. PubMed ID: 9865312
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of the development of murine systemic lupus erythematosus (SLE)-like diseases by the malononitrilamides MNA 279 and MNA 715.
    Schorlemmer HU, Bartlett RR.
    Inflamm Res; 1997 Aug; 46 Suppl 2():S167-8. PubMed ID: 9297564
    [No Abstract] [Full Text] [Related]

  • 9. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model.
    Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R.
    Transplant Proc; 1999 Aug; 31(1-2):1184-8. PubMed ID: 10083529
    [No Abstract] [Full Text] [Related]

  • 10. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents.
    Schorlemmer HU, Kurrle R, Bartlett RR.
    Drugs Exp Clin Res; 1997 Aug; 23(5-6):167-73. PubMed ID: 9515226
    [Abstract] [Full Text] [Related]

  • 11. Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model.
    Schorlemmer HU, Bartlett RR, Kurrle R.
    Transplant Proc; 1999 Aug; 31(1-2):851-3. PubMed ID: 10083371
    [No Abstract] [Full Text] [Related]

  • 12. Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs).
    Schorlemmer HU, Kurrle R, Bartlett RR.
    Inflamm Res; 1997 Aug; 46 Suppl 2():S165-6. PubMed ID: 9297563
    [No Abstract] [Full Text] [Related]

  • 13. Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis.
    Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR.
    Inflamm Res; 1999 Dec; 48 Suppl 2():S113-4. PubMed ID: 10667840
    [No Abstract] [Full Text] [Related]

  • 14. Autoimmune disease strongly resembling systemic lupus erythematosus (SLE) in F1 mice undergoing graft-versus-host reaction (GVHR).
    van der Veen FM, Rolink AG, Gleichmann E.
    Adv Exp Med Biol; 1982 Dec; 149():669-77. PubMed ID: 6983233
    [No Abstract] [Full Text] [Related]

  • 15. Hyperacute skin allograft rejection in presensitized rats is abrogated by malononitrilamides.
    Schorlemmer HU, Kurrle R.
    Transplant Proc; 1998 Jun; 30(4):963-7. PubMed ID: 9636390
    [No Abstract] [Full Text] [Related]

  • 16. Malononitrilamides inhibit T- and B-cell responsiveness.
    Kurrle R, Bartlett R, Ruuth E, Lauffer L, Schorlemmer HU.
    Transplant Proc; 1996 Dec; 28(6):3053-6. PubMed ID: 8962184
    [No Abstract] [Full Text] [Related]

  • 17. Quercitrin ameliorates the development of systemic lupus erythematosus-like disease in a chronic graft-versus-host murine model.
    Li W, Li H, Zhang M, Wang M, Zhong Y, Wu H, Yang Y, Morel L, Wei Q.
    Am J Physiol Renal Physiol; 2016 Jul 01; 311(1):F217-26. PubMed ID: 26911849
    [Abstract] [Full Text] [Related]

  • 18. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease.
    Chen F, Maldonado MA, Madaio M, Eisenberg RA.
    J Immunol; 1998 Dec 01; 161(11):5880-5. PubMed ID: 9834067
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamides.
    Schorlemmer HU, Bartlett RR, Kurrle R.
    Transplant Proc; 1998 Jun 01; 30(4):968-70. PubMed ID: 9636391
    [No Abstract] [Full Text] [Related]

  • 20. Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes.
    Girardi M, Herreid P, Tigelaar RE.
    J Invest Dermatol; 1995 Feb 01; 104(2):177-82. PubMed ID: 7829872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.